Sentences with phrase «buildup of amyloid»

A buildup of amyloid beta (Aβ) peptides are thought to be the cause of Alzheimer's disease.

Poor quality sleep can lead to buildup of amyloid and tau, compounds linked to Alzheimer's disease.

A new study confirmed the link between sleepiness during the day and the buildup of amyloid in the brain.

Spinal fluid analyses and positron emission tomography (PET) scans can detect a key warning sign — buildup of amyloid - beta protein in the brain.

It not only prevented the buildup of amyloid beta (Aß), a sticky protein linked to Alzheimer's, but it also does not appear to produce the dangerous side effects of earlier versions tested in humans.

Recent research also has illuminated how the deadly cascade that leads to brain atrophy is set in motion: The buildup of amyloid plaques, working in tandem with certain gene mutations, sparks the formation of the renegade tau proteins.

The bulk of research scientists working on Alzheimer's have long believed that a buildup of amyloid «plaques» is central to the disease's development — and that therefore targeting this protein is the best chance for a cure.

«People with this gene mutation usually get Alzheimer's at around age 70 because of the buildup of amyloids due to the reduced activity of the protective enzyme,» says Tanzi.

Not exact matches

«Expanding our collaboration with Banner Alzheimer's Institute stands testament to our belief that preventing amyloid buildup is one of the most promising approaches to treating Alzheimer's disease,» said Novartis» chief medical officer, global head of drug development, and soon - to - be CEO Dr. Vas Narasimhan in a statement.

The «amyloid hypothesis» figures that a buildup of brain plaque is what leads to the cognitive decline that Alzheimer's patients experience.

For one, it would give them three specific biological markers to hone in on: The buildup of beta amyloid and tau proteins, which cause brain plaques associated with Alzheimer's, and brain nerve cell death.

Unlike some of the promising treatments that have failed in 2017 that deal with the so - called «amyloid hypothesis» (the treatments target amyloid beta deposits in the brain that accumulate in people with Alzheimer's disease), approaches that try to prevent nerve cells from dying wouldn't have any impact on that buildup.

For example, Eli Lilly & Co. (NYSE: LLY) has a phase 3 study of solanezumab under way in mild to moderate Alzheimer's disease patients that may slow disease progression by breaking up amyloid plaque buildups thought to be a major cause of the disease.

The actual process of vascular aging may predispose a person's brain to the increased amount of amyloid plaque buildup.

Amyloid buildup is a key pathological feature of Alzheimer's, and determining the degree to which someone's brain is riddled with the molecule is essential for designing effective clinical trials.

And in a mouse model of Alzheimer's, having more TREM2 in the brain seemed to relieve inflammation and amyloid buildup, slow the loss of neurons and preserve the animals» cognitive abilities.

Several research groups have tried to clarify this issue using various methods to clear microglia from the brains of Alzheimer's mice to see how this would affect amyloid buildup.

According to the proposal, called the amyloid hypothesis, Alzheimer's disease, estimated to affect more than 5 million people in the United States alone, is caused by abnormal buildup of A-beta protein in the brain.

Researchers have proposed that Alzheimer's disease is caused by the buildup of a sticky protein called beta - amyloid.

Like cardiovascular disease, Alzheimer's involves the buildup of plaque, in this case tangled beta - amyloid proteins in the brain.

«If you prevent the buildup of beta amyloid, do you change the course of the disease?

«Activation of these cell receptors appear to prevent brain cells from cleaning out the trash — the toxic buildup of proteins, such as alpha - synuclein, tau and amyloid, common in neurodegenerative diseases,» says the study's senior author, neurologist Charbel Moussa, MBBS, PhD, director of Georgetown's Laboratory for Dementia and Parkinsonism, and scientific and clinical research director of the GUMC Translational Neurotherapeutics Program.

More than 40 illnesses known as amyloid diseases — Alzheimer's, Parkinson's and rheumatoid arthritis are a few — are linked to the buildup of proteins after they have transformed from their normally folded, biologically active forms to abnormally folded, grouped deposits called fibrils or plaques.

The main hypothesis on the cause of Alzheimer's involves amyloid deposition, the buildup of plaques in the brain that impair neurological function; most biomedical efforts to tackle the disease have focused on this issue.

Many neuroscientists believe that a buildup in the brain of a protein fragment called beta - amyloid causes Alzheimer's disease.

BUILDUP Amyloid - beta (brown) accumulated in the front of the brain in a person who received injections of cadaver - derived growth hormone as a child, suggesting that the injections were contaminated with A-beta, researchers reported this year.

BUILDUP Amyloid - beta (brown) accumulated in the front of the brain in a person who received injections of cadaver - derived growth hormone as a child, suggesting that the injections were contaminated with A-beta.

The disease is largely attributed to an abnormal buildup of proteins, which can form amyloid beta plaques and tangles in the brain that trigger inflammation and result in the loss of brain connections called synapses, the effect most strongly associated with cognitive decline.

The new therapy targets beta - secretase, an enzyme on neurons around which plaques (buildups of a protein called beta - amyloid) cluster in the brain.

The DNA change may inhibit the buildup of β amyloid, the protein fragment that accumulates in the hallmark plaques that form in the brains of Alzheimer's patients.

The overall goal of the A4 study is to test whether decreasing amyloid with antibody investigational treatment can help slow the memory loss associated with amyloid buildup in some people.

While the buildup of sticky proteins called amyloid plaques in the brain has been repeatedly linked to Alzheimer's disease, the role of blood in the formation of the condition has been less clear.

Although beta - amyloid buildup is a sign of Alzheimer's, it doesn't doom one to the disease, and might only be a sign of other aging processes, Vemuri suggested.

From that spinal fluid, the researchers found that people who reported poor sleep quality had, on average, more markers of Alzheimer's disease — including amyloid and tau buildups, brain - cell damage, and inflammation.

As I mentioned, a major trigger of memory loss is the buildup of beta - amyloid plaques in the brain.

Exciting new research shows that curcumin stops the process that causes the buildup of beta - amyloid plaques in the brain!

According to the authors, vascular damage may predispose your brain to increased amyloid plaque buildup, which is a hallmark of this degenerative brain disease.

They also found that it plays a role in preventing the buildup of beta - amyloid plaque, which can be found in the brain of Alzheimer's patients.

One of the waste products cleared during sleep is beta amyloid so Alzheimer's may just be a buildup of waste that hasn't been cleared over time.